1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Morphic Shows Potential For An ‘Oral Entyvio’ With Phase IIa Data

 
• By Joseph Haas

MORF-057, addressing the same target as Takeda blockbuster Entyvio, shows efficacy and safety in ulcerative colitis. Various companies have sought an oral competitor to established biologics in UC.

Biz competition
Morphic made progress in the race for an oral therapy in UC • Source: Shutterstock

Although the data are only from a small, open-label study, Morphic Therapeutic, Inc. generated excitement from shareholders and analysts on 25 April with top-line data showing its selective alpha-4 beta-7 (ɑ4β7) integrin inhibitor MORF-057 could offer similar efficacy in ulcerative colitis patients to Takeda Pharmaceutical Co. Ltd.’s injectable blockbuster Entyvio (vedolizumab), with a clean safety profile.

Morphic needed a win following the exits of AbbVie Inc. last June and Janssen Pharmaceutica Inc. in January from partnerships around its oral integrin inhibitor R&D platform. (Also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.